Prognostic nutritional index before adjuvant chemotherapy predicts chemotherapy compliance and survival among patients with non-small-cell lung cancer

被引:23
作者
Shimizu, Katsuhiko [1 ]
Okita, Riki [1 ]
Saisho, Shinsuke [1 ]
Yukawa, Takuro [1 ]
Maeda, Ai [1 ]
Nojima, Yuji [1 ]
Nakata, Masao [1 ]
机构
[1] Kawasaki Med Sch, Dept Gen Thorac Surg, Kurashiki, Okayama 7010192, Japan
关键词
non-small-cell lung cancer; adjuvant chemotherapy; prognostic nutritional index; treatment compliance; VINORELBINE PLUS CISPLATIN; GASTRIC-CANCER; WEIGHT-LOSS; ASSOCIATION; OUTCOMES; SURGERY; TEGAFUR; URACIL; S-1;
D O I
10.2147/TCRM.S92961
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Adjuvant chemotherapy after the complete resection of non-small-cell lung cancer (NSCLC) is now the standard of care. To improve survival, it is important to identify risk factors for the continuation of adjuvant chemotherapy. In this study, we analyzed chemotherapy compliance and magnitude of the prognostic impact of the prognostic nutritional index (PNI) before adjuvant chemotherapy. Methods: We conducted a retrospective review of data from 106 patients who had received adjuvant chemotherapy. The adjuvant chemotherapy consisted of an oral tegafur agent (OT) or platinum-based chemotherapy (PB). The correlations between the PNI values and recurrencefree survival (RFS) were then evaluated. Results: In the PB group, the percentage of patients who completed the four planned cycles of chemotherapy was not correlated with the PNI. In the OT group, however, a significant difference was observed in the percentage of patients who completed the planned chemotherapy according to the PNI before adjuvant chemotherapy. The RFS of patients with a PNI,50 before adjuvant chemotherapy was significantly poorer than that of the patients with a PNI >= 50. A multivariate analysis showed that nodal metastasis and PNI before chemotherapy were independent predictors of the RFS. However, PNI before surgery was not a predictor of the RFS. In the subgroup analysis, PNI before chemotherapy was independent predictor of the RFS in the OT group (P=0.019), but not in the PB group (P=0.095). Conclusion: The PNI before adjuvant chemotherapy influenced the treatment compliance with the planned chemotherapy in the OT group, but not the PB group. In addition, a low PNI before adjuvant chemotherapy was associated with a poor RFS in a multivariate analysis, especially in the OT group.
引用
收藏
页码:1555 / 1561
页数:7
相关论文
共 26 条
[1]  
Andreoli A, 2011, EUR REV MED PHARMACO, V15, P469
[2]   Body Weight Loss After Surgery is an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer [J].
Aoyama, Toru ;
Yoshikawa, Takaki ;
Shirai, Junya ;
Hayashi, Tsutomu ;
Yamada, Takanobu ;
Tsuchida, Kazuhito ;
Hasegawa, Shinichi ;
Cho, Haruhiko ;
Yukawa, Norio ;
Oshima, Takashi ;
Rino, Yasushi ;
Masuda, Munetaka ;
Tsuburaya, Akira .
ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (06) :2000-2006
[3]   Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study [J].
Arrieta, Oscar ;
Michel Ortega, Rosa M. ;
Villanueva-Rodriguez, Geraldine ;
Serna-Thome, Maria G. ;
Flores-Estrada, Diana ;
Diaz-Romero, Consuelo ;
Rodriguez, Cindy M. ;
Martinez, Luis ;
Sanchez-Lara, Karla .
BMC CANCER, 2010, 10
[4]   DOSE-RESPONSE EFFECT OF ADJUVANT CHEMOTHERAPY IN BREAST-CANCER [J].
BONADONNA, G ;
VALAGUSSA, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (01) :10-15
[5]   A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): Paclitaxel plus carboplatin versus vinorelbine plus cisplatin [J].
Chang, Won Jin ;
Sun, Jong-Mu ;
Lee, Ji Yean ;
Ahn, Jin Seok ;
Ahn, Myung-Ju ;
Park, Keunchil .
LUNG CANCER, 2014, 84 (01) :51-55
[6]   Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer [J].
Colleoni, M ;
Price, K ;
Castiglione-Gertsch, M ;
Goldhirsch, A ;
Coates, A ;
Lindtner, J ;
Collins, J ;
Gelber, RD ;
Thürlimann, B ;
Rudenstam, CM .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (11) :1693-1700
[7]   Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]):: a randomised controlled trial [J].
Douillard, Jean-Yves ;
Rosell, Rafael ;
De Lena, Mario ;
Carpagnano, Francesco ;
Ramlau, Rodryg ;
Gonzales-Larriba, Jose Luis ;
Grodzki, Tornasz ;
Pereira, Jose Rodrigues ;
Le Groumellec, Alain ;
Lorusso, Vito ;
Clary, Claude ;
Torres, Antonio J. ;
Dahabreh, Jabrail ;
Souquet, Pierre-Jean ;
Astudillo, Julio ;
Fournel, Pierre ;
Artal-Cortes, Angel ;
Jassem, Jacek ;
Koubkova, Leona ;
His, Patricia ;
Riggi, Marcella ;
Hurteloup, Patrick .
LANCET ONCOLOGY, 2006, 7 (09) :719-727
[8]   Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer [J].
Hamada, C ;
Tanaka, F ;
Ohta, M ;
Fujimura, S ;
Kodama, K ;
Imaizumi, M ;
Wada, H .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :4999-5006
[9]  
Iwamoto Y, 2015, CLIN CANC RES
[10]   Nutritional predictors of postoperative outcome in pancreatic cancer [J].
Kanda, M. ;
Fujii, T. ;
Kodera, Y. ;
Nagai, S. ;
Takeda, S. ;
Nakao, A. .
BRITISH JOURNAL OF SURGERY, 2011, 98 (02) :268-274